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Abstract  The  future  challenges  in  oncology  imaging  are  to  assess  the  response  to  treatment
even earlier.  As  an  addition  to  functional  imaging,  mathematical  modeling  based  on  the  imaging
is an  alternative,  cross-disciplinary  area  of  development.  Modeling  was  developed  in  oncology
not only  in  order  to  understand  and  predict  tumor  growth,  but  also  to  anticipate  the  effects
of targeted  and  untargeted  therapies.  A  very  wide  range  of  these  models  exist,  involving  many
stages in  the  progression  of  tumors.  Few  models,  however,  have  been  proposed  to  reproduce
in vivo  tumor  growth  because  of  the  complexity  of  the  mechanisms  involved.  Morphological
imaging combined  with  ‘‘spatial’’  models  appears  to  perform  well  although  functioning  imaging
could still  provide  further  information  on  metabolism  and  the  micro-architecture.  The  combina-
tion of  imaging  and  modeling  can  resolve  complex  problems  and  describe  many  facets  of  tumor
growth or  response  to  treatment.  It  is  now  possible  to  consider  its  clinical  use  in  the  medium
term. This  review  describes  the  basic  principles  of  mathematical  modeling  and  describes  the
advantages,  limitations  and  future  prospects  for  this  in  vivo  approach  based  on  imaging  data.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Nowadays,  imaging  lies  at  the  heart  of  patient  management,  particularly  in  oncology.
Apart  from  the  time  when  a  disease  is  diagnosed,  the  different  imaging  methods  are  used
to  assess  the  effectiveness  of  both  local  (surgery,  radiotherapy,  heat  ablation)  and  systemic
(chemotherapy,  targeted  therapy)  treatments  during  follow-up.  The  protocols  usually  rec-
ommend  assessment  criteria  such  as  the  RECIST,  WHO  or  CHOI,  although  these  are  less
than  perfect  [1].
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Nevertheless,  the  future  challenges  for  imaging  are  to
ssess  response  to  treatment  and  to  change  treatment  even
arlier,  making  it  increasingly  targeted  and  appropriate  and
s  soon  as  possible  if  necessary.  This  approach  can  optimize
reatment  and  reduce  costs.  At  present  it  is  based  mostly
n  functional  imaging,  which  is  expanding  greatly  [2]. This
spect  of  imaging  provides  considerable  information  about
ellular  activity  (PET),  nutrient  consumption  [3],  angiogen-
sis  and  capillary  permeability  (perfusion  MRI)  [4]  and  also
issue  micro-architecture  (diffusion  MRI)  [2], to  name  a  few
xamples.  In  this  situation,  modeling  may  be  an  alternative,
ross-disciplinary  area  of  development.
Mathematical  modeling  has  been  developed  in  oncology
n  order  both  to  understand  and  predict  tumor  growth  and  to
nticipate  the  effects  of  targeted  or  non-targeted  therapies
e.g.  the  anti-angiogenics).  There  is  a  very  wide  range  of
hese  models  involving  many  stages  in  tumor  progression.
hey  can,  for  example,  help  to  understand  the  inﬂuence  of
enetic  regulation  [5]  or  predict  an  effect,  which  has  been
bserved  experimentally  [6].
In  most  of  these  cases,  however,  the  models  are  better
uited  for  in  vitro  studies  as  they  are  often  focused  on  a
mall  cell  contingent,  progression  of  which  is  more  straight-
orward  to  observe.  The  problem  in  vivo  becomes  more
omplex  as  it  needs  to  take  account  of  an  entire  tumor  con-
aining  a  large  number  of  cells  and  therefore  mechanisms
o  be  elucidated.  In  addition,  unlike  in  vitro  studies,  the
mount  of  information  available  without  modeling  a  tumor
n  vivo  is  very  little  as  it  is  ‘‘swamped’’  by  the  large  num-
er  of  cells  and  therefore  also  with  signals.  It  would  appear
ssential  therefore  to  develop  appropriate  means  to  col-
ect  the  maximum  of  information  in  order  to  optimize  these
odels.
Apart  from  biopsies,  which  provide  microscopic  infor-
ation,  albeit  from  limited  samples,  imaging  examinations
ave  become  essential  as  they  allow  repeated,  non-invasive
nformation  to  be  recovered  over  time.  The  size  (or  volume),
hape,  site  and  uptake  after  contrast  injection  are  rela-
ively  easy  parameters  to  obtain  whereas  micro-architecture
r  perfusion  data  are  still  difﬁcult  and  depend  on  the  tar-
et  organ.  The  information  obtained  can  be  used  to  reﬁne
odels  and  ultimately  be  applied  to  clinical  practice.
This  review  explains  the  basic  principles  of  mathemati-
al  modeling  and  describes  the  advantages,  limitations  and
uture  prospect  of  this  in  vivo  approach  based  on  imaging
ata.
oncepts of modeling tumor growth
ntirely  schematically,  several  successive  stages  can  be
dentiﬁed  in  the  growth  of  a  solid  tumor  due  to  deregula-
ion  of  cell  division:  initial  avascular  growth,  angiogenesis,
nd  ﬁnally  metastatic  spread.
During  the  avascular  growth  phase,  the  tumor  (according
o  the  monoclonal  hypothesis  of  cancer,  the  tumor  initially
onsists  of  a  single  abnormal  cell)  grows  within  the  limits
f  its  local  environment  in  a  characteristic  ‘‘layer’’  model
7].  Nutrient  supply  to  the  centre  of  the  tumor  is  inadequate
nd  necrosis  may  occur.  A  layer  of  quiescent  cells,  which  sur-
ive  without  dividing  with  limited  slow  metabolism,  is  found
etween  the  two  layers.  According  to  this  type  of  model,
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umor  growth  is  then  severely  restricted  and  in  order  to  con-
inue  growing  it  needs  to  ﬁnd  additional  nutrient  sources.
he  tumor  then  enters  its  second  stage  of  growth,  the  vascu-
ar  phase.  As  a  result  of  hypoxic  pressure  some  phenotypes
an  be  favored  (through  Darwinian  selection).  Some  cells
hen  produce  signals  (such  as  VEGF),  which  encourage  the
ody  to  vascularize  the  tumor  and  therefore  provide  it  with
ew  nutrients  (this  is  the  process  of  angiogenesis).  It  is
mportant  to  be  aware  of  this  stage  for  several  reasons.
nce  it  is  vascularized  the  tumor  can  reach  signiﬁcantly  far
arger  sizes  than  in  the  previous  stage  and  then  be  visible  on
maging.  Finally,  vascular  fragmentation  leads  to  metastatic
pread.
It  is  therefore  not  difﬁcult  to  understand  that  because
f  the  complexity  of  the  processes  involved  in  all  of  these
tages,  mathematical  models  are  to  a large  extent  phe-
omenologic  and  extremely  simpliﬁed  compared  to  what
appens  in  biological  reality.  Two  main  types  of  modeling
an  be  distinguished,  which  depend  on  whether  or  not  the
umor  is  integrated  into  its  neighbouring  space.
Non-spatial  models  calculate  the  change  in  one  or  more
ajor  appropriate  scales  in  order  to  monitor  tumor  growth.
lassic  examples  are  models  based  on  ordinal  differential
quations  (ODE),  which  describe  the  change  in  volume  or
adius  of  the  tumor.  These  do  not  take  account  of  the
umor  environment  or  its  interactions  but  just  of  measurable
imensions  [8].  These  models  are,  however,  too  simple  to
rovide  useful,  reliable,  reproducible  information  about  the
umor  from  the  phenomenologic  change  in  its  volume,  which
aries  at  random  between  different  tumors  and  patients.
hey  may,  however,  be  made  more  complex  to  incorporate
everal  compartments  (depending  on  the  cell  cycle)  or  to
ake  account  of  different  processes  such  as  angiogenesis.
Conversely,  the  spatial  model  takes  into  account  of  the
umor  environment.  Several  methods  have  been  proposed  to
odel  tumor  growth  in  this  way  [9,10].  One  involves  describ-
ng  the  progression  of  cells  individually  [11]  and  produces
‘discrete’’  automated  cell  models  [12]  or  agent  models
13]. These  relatively  simple  models  are  very  effective  in
imulating  in  vitro  growth  to  describe  microscopic  effects
nd  link  them  to  the  molecular  level  [14].  However,  it  does
ot  seem  currently  possible  to  model  an  entire  complex  of
ells  in  its  environment,  i.e.  an  entire  tumor,  as  this  is  too
ifﬁcult  and  technically  complex.
Another  approach  to  spatial  modeling  involves  working
n  several  cells  or  population  of  cells  at  the  same  time
nd  therefore  describing  the  change  in  cell  densities  (or  the
oundaries  of  tumors  for  example).  This  allows  tumors  of
ealistic  size  to  be  studied  and  takes  account  of  macroscopic
ffects  (for  example,  interactions  between  cells  and  an
xtracellular  membrane  or  cellular  adhesion)  using  models
nspired  from  continuous  medium  mechanics  [15].  The  tissue
tudied  is  then  treated  as  a  continuum  governed  by  a  behav-
or  law  in  the  medium.  It  is  thus  straightforward  to  take
ccount  of  an  extensive  complex  environment  although  it  is
ifﬁcult  to  take  all  of  the  independent  and  non-independent
icroscopic  effects  [15]  into  account.  Some  models  do  how-
ver,  take  angiogenesis  into  account  [14,16],  and  others  pay
ore  attention  to  chemotaxis  [17].  In  parallel,  in  terms  ofissue  description,  both  mono-  and  multiphase  cell  popu-
ation  interaction  models  have  been  studied  [18,19].  Cell
ycle  modeling  has  also  been  studied  [20], with  a  view  to
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optimizing  treatment  [21—23].  These  spatial  models  can
therefore  incorporate  a  2  (or  more)  phase  cell  cycle,  one  of
proliferating  cells  and  the  other  of  quiescent  cells,  and  also
take  account  of  a  necrosis  phase.  In  addition,  oxygen  diffu-
sion,  angiogenesis  and  interactions  with  membranes  [24]  or
neighbouring  tissues  can  also  be  taken  into  account.
These  spatial  models  have  the  advantage  of  incorporat-
ing  far  more  biological  knowledge  and  have  several  beneﬁts,
which  justify  their  use.  They  are  said  to  reproduce  realistic
behavior,  with  the  desired  purpose,  and  can  also  test  cell
interaction  hypotheses  [25]  in  an  entity  such  as  a  tumor.
They  are  often,  however,  very  complex,  as  they  contain
experimentally  inaccessible  parameters  and  are  not  spe-
ciﬁc  for  a  patient,  as  parameters  vary  greatly  in  different
situations.  They  are  not  therefore  suitable  for  clinical  use.
In  order  to  adapt  the  spatial  models  to  each  disease  and
patient,  they  therefore  need  to  be  simpliﬁed  and  calibrated
with  clinical  data  which  can  be  obtained  for  example  by
imaging  in  order  to  estimate  the  different  parameters  in
the  equations  and  therefore  obtain  quantitative  results.
Spatial mathematical models based on
imaging
All  of  the  information  available  from  morphological  imaging
can  be  used  in  mathematical  modeling.  Dimensions,  vol-
ume,  density  and  intensity  are  those  which  are  used  most
often.  Changes  over  time  provide  additional  information.
The  use  of  functional  imaging  data  is  still  in  the  develop-
mental  phase  and  the  choice  of  a  model  will  also  depend  on
the  temporal  distribution  of  the  available  data,  as  statistical
models  require  more  data  than  determinist  models  to  start
the  modeling  process.
Statistical models
These  models  require  a  large  amount  of  initial  data.  Informa-
tion  obtained  from  imaging  investigations  often  exhibits  very
considerable  inter-individual  variability,  which  has  led  to  the
development  of  mixed  effect  regression  techniques  [26,27].
These  models  take  account  of  two  levels  of  variability:
inter-individual  variability  and  intra-individual  or  residual
variability  (as  is  seen  in  the  classical  regression  technique).
The  number  of  parameters  is  therefore  increased  as  each
parameter  consists  of  a  ﬁxed  component  (mean  parameter)
and  a  random  component,  hence  the  name  ‘‘mixed  effect’’.
Tham  et  al.  [26]  proposed  an  empirical  model  to  describe
the  effect  of  a  combination  of  two  drugs  on  tumor  size  in
patients  suffering  from  lung  cancer.  Wang  et  al.  [27]  went
further  by  developing  a  similar  model  from  a  lung  cancer
database  created  from  different  clinical  studies  and  there-
fore  involving  different  treatments.  The  authors  showed
that  some  variables  directly  derived  from  model  predictions
(initial  ‘‘baseline’’  tumor  size  and  reduction  in  tumor  size  3
weeks  after  starting  treatment)  were  predictive  indicators
for  survival.
If  the  purpose  of  modeling  is  to  assess  the  future  progres-
sion  of  a  disease  in  a  given  patient,  statistical  approaches
are  not  necessarily  the  most  appropriate.  These  provide
an  ‘‘average’’  response  provided  that  a  sufﬁcient  database
exists  containing  a  large  number  of  similar  cases  to  the  caseta  595
n  question.  These  models  can  also  be  made  more  complex
y  combining  molecular  marker  activity  with  this  simple
umor  growth  method  to  establish  a multi-scale  model  [28].
Even  so,  in  order  to  obtain  a  prognosis  for  a  given  tumor
n  a  given  patient,  statistical  modeling  contains  a large  mar-
in  of  error  and  does  not  appear  appropriate.  The  statistical
pproaches  may  however  be  useful  in  validating  and  select-
ng  the  model  and  measuring  its  accuracy  and  robustness.
eterminist models
s  described  above,  most  of  the  mathematical  models  used
linically  are  based  on  a  group  of  ordinal  differential  equa-
ions  (ODE)  and  describe  the  change  in  tumor  volume  [8].
he  spatial  dimension  (e.g.  shape  or  site  of  the  tumor)  is
ot  taken  into  account,  which  limits  the  use  of  the  data
btained  from  imaging  and  therefore  the  ability  to  estimate
he  parameters  in  the  equations.  In  order  to  compensate
or  this,  a  recent  model  has  been  developed  based  on  mor-
hological  study  of  different  lesions  with  sufﬁciently  well
eﬁned  outlines  to  extract  the  images  seen  after  segmen-
ation  and  repositioning  (Fig.  1)  [29].  Ordinal  differential
quation  (ODE)  and  partial  derived  equation  (PDE)  models
ere  then  used,  incorporating  different  pre-determined
arameters  whose  values,  however,  were  unknown.  These
arameters  were  estimated  using  two  approaches,  a  pop-
lation  approach  allowing  inter-patient  variability  to  be
ncorporated  and  an  individual  approach  based  on  2D  or  3D
nformation  in  order  to  incorporate  different  information
uch  as  treatment  strategy.
From  this  work  and  in  order  to  propose  a  simpliﬁed  model
hich  could  be  used  in  reality  with  the  limited  tumor  or
atient  information  generally  available,  the  cell  cycle  was
ontracted  into  a  PDE  no  longer  structured  by  age,  and  treat-
ng  a  population  of  proliferating  cells  (of  concentration  P)
Fig.  2).  Growth  rate  is  determined  by  local  oxygen  concen-
ration,  which  is  given  by  a  reaction-diffusion  equation.  If
he  oxygen  concentration  is  too  low  (hypoxia),  not  only  do
he  cells  not  proliferate  but  they  move  into  the  quiescent
hase  (shown  as  Q)  (the  phase  in  which  the  tumor  cells
emains  alive  but  cells  do  not  proliferate).  Conversely,  if  the
xygen  concentration  increases,  the  cells  can  return  to  the
roliferative  phase.  The  proliferative/quiescent  cell  ratio  is
n  indicator  of  tumor  aggression.  Cell  proliferation  leads  to
n  increase  in  volume,  which  is  described  as  the  divergence
f  a  velocity  ﬁeld,  which  has  to  be  determined.  This  veloc-
ty  ﬁeld  has  nothing  to  do  with  the  velocity,  for  example,
f  inﬁltrating  cells,  but  describes  the  overall  movement  of
he  tissue  due  to  its  increase  in  volume  limited  by  the  pres-
ure  of  the  surrounding  environment  according  to  Darcy’s
aw,  with  permeability  depending  on  the  tissue  (healthy  or
umor)  [30].  Finally,  oxygen  concentration  is  given  by  a  dif-
usion  equation  which  depends  on  the  type  of  tissue  and
hich  reﬂects  vascularization  with  absorption  factors  due
o  consumption  by  tumor  cells.
In  summary,  the  equations  which  describe  changes  in  den-
ity  P  and  Q  are  shown  below:
∂P∂t
+ ∇  ·  (vP)  =  (2  −  1)P  +  Q,
∂Q
∂t
+  ∇  · (vQ  ) =  (1  −  )P  +  Q
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Figure 1. Segmentation and repositioning of images. a, b: axial computed tomography sections showing a left lower lobe lung nodule in
the pulmonary and mediastinal windows respectively; c: the nodule is segmented in sections and visualized in 3D; d: the lung volume is also
segmented; e: several contours are shown illustrating the change over a same volume section, the shape and precision of a lung nodule on
the subsequent CT scans after repositioning; f: segmentation, repositioning and 3D visualization of the same nodule on three successive
investigations.
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Figure 2. Basic principle of modeling tumor growth. The pro-
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fliferating phase, P, and the quiescent phase, Q, depend on the
concentration of nutrients and oxygen (linked to ) provided in a
simpliﬁed way by vascularization.
where  the  function    describes  the  presence  or  absence  of
sufﬁcient  nutrients:
  = 1  +  tanh(C  −  Chyp)
2
where  C  represents  local  oxygen  concentration.  The  hypoxia
threshold  Chyp is  a  model  parameter,  which  describes  the
sensitivity  of  cells  to  hypoxia.  As  seen  previously,  in  this  case
cell  movement  is  deemed  to  be  due  only  to  cell  division  and
the  velocity  v  in  the  system  follows  Darcy’s  law.
Although  this  model  is  greatly  simpliﬁed,  it  already
contains  several  parameters,  which  need  to  be  identiﬁed
whereas  the  only  ﬁnding  provided  by  imaging  is  tumor  vol-
ume,  which  is  the  sum  of  variables  P  +  Q  in  the  model.  Based
only  on  morphological  imaging,  i.e.  by  studying  volume,
the  site,  shape  and  uptake  of  a  tumor  and  any  growth,
information  obtained  from  imaging  examinations  is  there-
fore  very  limited.
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The  calculation  strategy  is  as  follows:  for  a  given  patient,
he  images  must  ﬁrst  be  processed  digitally  (Fig.  1)  and  then
n  order  to  use  the  PDE  model  shown  schematically  in  Fig.  2,
ts  parameters  must  be  determined.  This  is  achieved  by
olving  an  inverse  problem  involving  a  large  number  of  calcu-
ations  using  several  radiological  investigations  as  the  input
ata.  Under  favorable  conditions  a  personalized  prediction
an  then  be  obtained.
These  models  are  undergoing  preclinical  evaluation  for
liomas,  lung  metastases  (Fig.  3)  and  some  stromal  tumors
gastrointestinal  stromal  tumor  [GIST])  (Fig.  4).  These
umors  have  the  advantage  that  it  is  easy  to  deﬁne  their  out-
ines  and  can  be  followed  up  for  relatively  long  periods  of
ime  with  or  without  treatment.  A  large  amount  of  informa-
ion  about  their  progression  is  therefore  available.  As  shown
n  Fig.  3, it  is  already  possible  to  obtain  a  quantitative  pre-
iction  for  untreated  lung  metastases.  A  prediction  is  not  yet
ossible  for  hepatic  GIST  metastases  (Fig.  4),  although  the
esponse  to  treatment  and  loss  of  treatment  response  phase
an  be  reproduced.  The  modeling  techniques  are  described
n  detail  in  reference  [30].
uture prospects
lthough  the  clinical  use  of  spatial  mathematical  models
s  far  from  being  actually  effective,  they  have  many
hort  and  medium  term  future  prospects  in  the  clin-
cal  assessment  in  surgery  or  interventional  radiology
y  determining  tumor  margins  or  optimizing  needle
ositioning  (for  example,  thermal  heat  ablation  or
ryotherapy).
Whilst  some  aspects  of  tumor  growth  are  not  determin-
st  (for  example,  spontaneous  genetic  mutations  and  the
mergence  of  phenotypes  which  are  resistant  to  therapy)
nd  cannot  therefore  be  incorporated  into  these  models
or  a  speciﬁc  approach  to  a  given  patient,  this  work  can
nable  early  changes  due  to  these  mutations  to  be  identi-
ed  from  a  deviation  from  the  medical  ﬁndings  in  relation  to
he  digital  prediction.  Treatments  can  therefore  be  adjusted
arlier.
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Figure 3. Modeling tumor growth of lung metastases. a, b, c: axial computed tomography sections showing a right lower lobe lung
nodule on successive CT scans without any treatment. Only images a and b are used in the calculation. Subsequent investigations are
simply used to validate our method; d: change in volume of the nodule over time: actual observations (round) and those obtained from
calibrated modeling (curve). The red square is the volume actually measured on an investigation performed after the model was calibrated;
e: computed tomography axial section with representation of the tumor calculated at the same time (red) as investigation of the image c.
In  vivo  mathematical  modeling  of  tumor  growth  from  imaging  data  599
Figure 4. Modeling of tumor growth of hepatic GIST metastases. a, b: computed tomography axial sections with injection showing a hepatic
nodule in segment IV on two successive scans; c: change in volume over time on the actual observations. These changes take account of
successive anti-tyrosine kinase treatments (decreased phase) followed by an anti-angiogenic after failure to respond further to treatment;
d: change in volume of the nodule over time from modeling. This initial completely spatial model (PDE) takes, at least qualitatively, account
of the control phase with the anti-tyrosine kinase then the loss of response and ﬁnally the control by anti-angiogenic. These results are not
predictions as all of the data are used to obtain the simulated curves; e: this second modeling (ODE) takes quantitative account in terms of
the cell population in the control phase and then the loss of response. These results are not predictions as all of the data are used to obtain
the simulated curves.
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onclusion
hereas  many  technical  challenges  remain  to  be  resolved
nd  cannot  be  ignored,  mathematical  modeling  of  tumor
rowth  even  if  simplistic  is  now  a  reality.  Imaging  appears  to
e  a  valuable  aid  in  solving  the  different  problems  raised.
he  input  of  further  information  from  functional  imaging
ill  help  to  facilitate  the  resolution  of  current  models  and
ither  to  predict  the  development  and  use  of  the  more  pre-
ise  models  in  order  to  come  closer  to  the  real  life  biological
ituation.
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